Share on LinkedInShare on LinkedIn

ARTICLE · 12 APRIL 2016

Recent Developments In Clinical Data Exclusivity

Mexico, along with the United States and Canada, was one of the first countries to sign data protection provisions in a free trade agreement.

MexicoFood, Drugs, Healthcare, Life Sciences

Evolution of data exclusivity

Mexico, along with the United States and Canada, was one of the first countries to sign data protection provisions in a free trade agreement. The North American Free Trade Agreement (NAFTA) included obligations related to the protection of data submitted before regulatory agencies well before the Agreement on Trade-Related Aspects of IP Rights (TRIPs).

Paragraphs 5 to 7 of Article 1711 of NAFTA contain specific provisions with regard to data submitted to entities in charge of granting market approvals for pharmaceutical and agrochemical products, with the main obligation imposed on the contracting states to prevent unfair commercial use of such information. NAFTA has always been considered a more specific standard for the protection of clinical data than TRIPs, as it provides for a minimum standard of five years of protection from the date that market authorisation was granted.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from